This is not the most recent version of the article. View current version (4 AUG 2010)

Intervention Protocol

You have free access to this content

Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)

  1. Arash Afshari1,*,
  2. Jesper Brok2,
  3. Ann Merete Møller3,
  4. Jørn Wetterslev4

Editorial Group: Cochrane Anaesthesia Group

Published Online: 15 APR 2009

DOI: 10.1002/14651858.CD007733


How to Cite

Afshari A, Brok J, Møller AM, Wetterslev J. Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007733. DOI: 10.1002/14651858.CD007733.

Author Information

  1. 1

    Rigshospitalet, The Cochrane Anaesthesia Review Group & Copenhagen Trial Unit and Department of Paediatric and Obstetric Anaesthesia, Copenhagen, Denmark

  2. 2

    Hvidovre Hospital, Paediatric Department, Hvidovre, Denmark

  3. 3

    Herlev University Hospital, Department of Anaesthesiology, Herlev, Denmark

  4. 4

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

*Arash Afshari, The Cochrane Anaesthesia Review Group & Copenhagen Trial Unit and Department of Paediatric and Obstetric Anaesthesia, Rigshospitalet, Blegdamsvej 9, Afsnit 3342, rum 52, Copenhagen, 2100, Denmark. arriba.a@gmail.com. afshari@rocketmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 15 APR 2009

SEARCH

This is not the most recent version of the article. View current version (04 AUG 2010)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

We will assess the benefits and harms of aerosolized prostacyclin for ALI/ARDS in adults and children as our primary objective. Furthermore, we will look at various outcomes, conduct subgroup and sensitivity analyses, examine the role of bias and apply trial sequential analyses (TSA) to examine the level of evidence.